Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Halozyme Therapeutics
So what: Already owner of 7.5% of the biotech's outstanding shares, according to S&P Capital IQ, Kirk bought more than 277,000 shares last week. The biggest transaction -- for 166,100 shares -- came just before the Thanksgiving holiday.
Now what: Halozyme has been a huge winner since October, when the company and its distribution partner, Roche Holding, reported positive phase 3 trial results for breast cancer treatment Herceptin. Kirk apparently sees FDA approval as all but assured. Do you agree? Would you buy shares of Halozyme Therapeutics at current prices? Please weigh in using the comments box below.
Interested in more information about Halozyme Therapeutics? Add it to your watchlist.
Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim's portfolio holdings and Foolish writings, or connect with him on Google+ or Twitter, where he goes by @milehighfool. You can also get his insights delivered directly to your RSS reader.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This News Explains Halozyme Therapeutics' Double-Digit Drop Today
Shares fall after an analyst lowers his price target. Here's what investors need to know.
3 Top Stocks Wall Street Is Overlooking
Just because investors are ignoring these three gems doesn't mean that you have to.
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
Investors cheer better-than-expected earnings and a guidance boost. Could there be more upside ahead?